High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019 | Zendy

Wei Cao | Zendy; Xiaosheng Liu | Zendy; Tao Bai | Zendy; Hongwei Fan | Zendy; Ke Hong | Zendy; Hui Song | Zendy; Yang Han | Zendy; Ling Lin | Zendy; Lianguo Ruan | Zendy; Taisheng Li | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019

Author(s) -

Wei Cao,

Xiaosheng Liu,

Tao Bai,

Hongwei Fan,

Ke Hong,

Hui Song,

Yang Han,

Ling Lin,

Lianguo Ruan,

Taisheng Li

Publication year - 2020

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofaa102

Subject(s) - medicine , covid-19 , antibody , outbreak , coronavirus , disease , intravenous immunoglobulins , immunology , virology , infectious disease (medical specialty)

The outbreak of coronavirus disease 2019 (COVID-19) has spread rapidly in China. Until now, no definite effective treatment has been identified. We reported on 3 patients with severe COVID-19 who received high-dose intravenous immunoglobulin (IVIg) with satisfactory recovery. Based on these observations, randomized studies of high-dose IVIg should be considered in deteriorating patients infected with COVID-19.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research